Relay Therapeutics Adds Dr. Claire Mazumdar to Board

By Tamara Parker • Thursday, June 12 10:10 • Permanent Link

Relay Therapeutics, Inc. (NASDAQ: RLAY) has recently welcomed Dr. Claire Mazumdar, Ph.D., to its board of directors, effective June 9, 2025. Dr. Mazumdar, with her strategic and operational experience in clinical-stage oncology, is expected to provide guidance as the company prepares to initiate its phase 3 Rediscover-2 trial in breast cancer.

Dr. Mazumdar, the founding CEO of Bicara Therapeutics (NASDAQ: BCAX), brings a wealth of experience from her previous roles in business development and corporate strategy at Rheos Medicines, as well as her time at Third Rock Ventures. With a strong educational background, including a B.S. in biological engineering from the Massachusetts Institute of Technology, an MBA from Stanford Graduate School of Business, and a Ph.D. in cancer biology from Stanford School of Medicine, Dr. Mazumdar's appointment is anticipated to be beneficial for Relay Therapeutics.

Relay Therapeutics, a clinical-stage precision medicine company, is focused on transforming the drug discovery process through the integration of computational and experimental technologies. The company's Dynamo® platform combines these advanced approaches to target protein therapeutics, with an initial focus on small molecule therapeutic discovery in targeted oncology and genetic disease indications.

As of the latest report, the company's stock is listed as NASDAQ: RLAY. The specifics of how the company's metrics have changed since the last period were not provided in the press release. The market has reacted to these announcements by moving the company's shares -4.3% to a price of $3.34. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.